BAX 326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B - A Continuation Study
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006637/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this BAX 326 Continuation Study is to further investigate incremental recovery
over time, the hemostatic efficacy, the safety, immunogenicity, and health-related quality of
life (HR QoL) of BAX 326 in previously treated patients (PTPs) with severe and moderately
severe hemophilia B who participated in BAX 326 pivotal study 250901 or BAX 326 pediatric
study 251101.
提供机构：
Vivli
创建时间：
2021-02-02
